Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas
Próximo webinar (presencial y telemático) sobre GOLD 2026
Descubre las novedades del informe GOLD 2026 en este webinar gratuito desde la Universidad de Barcelona. Participa online o presencialmente.
Treatable Traits. Why, What, How?
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
Origenes tempranos de las enfermedades crónicas del adulto
Charla de Alvar Agistí en el H. La Paz sobre los orígenes de las enfermedades crónicas. tempranos en la sesión titulada: Orígenes tempranos de las enfermedades crónicas del adulto. El 24/09/2025
Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
COPD multimorbidity management: A person-centred clinical approach to the multimorbid patient with COPD
Expert consensus on patient-centred strategies to manage multimorbidity in COPD, aiming to improve outcomes and reduce disease burden.
Imagen obtenida de la presentación